Patients diagnosed with GBM, hepatocellular carcinoma, pancreatic, colorectal, breast or gastric cancer, among others, who express MUC-1, were enrolled for MUC-1-directed CAR-NK cell therapy; however, as of April 2021, the results are still awaited. The gene discussed is MUC1; the disease is hepatocellular carcinoma.